Sunshine Biopharma, Inc.
Sunshine Biopharma, Inc. (SBFMW) Stock Overview
Explore Sunshine Biopharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.
SBFMW Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Sunshine Biopharma, Inc. (SBFMW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.02.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.20 and a market capitalization of 7.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Steve N. Slilaty
52
6500 Trans-Canada Highway, Pointe-Claire, QC
2022